文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

嵌合抗原受体自然杀伤细胞疗法治疗恶性肿瘤的临床前和临床研究。

Preclinical and clinical studies of CAR-NK-cell therapies for malignancies.

机构信息

Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.

State Key Laboratory of Esophageal Cancer Prevention and Treatment and Henan Key Laboratory for Esophageal Cancer Research, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.

出版信息

Front Immunol. 2022 Oct 24;13:992232. doi: 10.3389/fimmu.2022.992232. eCollection 2022.

DOI:10.3389/fimmu.2022.992232
PMID:36353643
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9637940/
Abstract

The development of chimeric antigen receptor T (CAR-T) cell therapy, a specific type of immunotherapy, in recent decades was a fantastic breakthrough for the treatment of hematological malignancies. However, difficulties in collecting normal T cells from patients and the time cost of manufacturing CAR-T cells have limited the application of CAR-T-cell therapy. In addition, the termination of related clinical trials on universal CAR-T cell therapy has made further research more difficult. Natural killer (NK) cells have drawn great attention in recent years. Chimeric antigen receptor-NK (CAR-NK) cell therapy is a promising strategy in the treatment of malignant tumors because of its lack of potential for causing graft-versus-host disease (GVHD). In this review, we will address the advances in and achievements of CAR-NK cell therapy.

摘要

嵌合抗原受体 T（CAR-T）细胞疗法是一种特定类型的免疫疗法，近几十年来的发展是血液系统恶性肿瘤治疗的一个惊人突破。然而，从患者中收集正常 T 细胞的困难和制造 CAR-T 细胞的时间成本限制了 CAR-T 细胞疗法的应用。此外，通用 CAR-T 细胞疗法相关临床试验的终止使得进一步的研究更加困难。近年来，自然杀伤（NK）细胞引起了极大的关注。嵌合抗原受体-NK（CAR-NK）细胞疗法因其缺乏引起移植物抗宿主病（GVHD）的潜力而成为治疗恶性肿瘤的一种很有前途的策略。在这篇综述中，我们将讨论 CAR-NK 细胞疗法的进展和成就。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5469/9637940/88a15021e21a/fimmu-13-992232-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5469/9637940/88a15021e21a/fimmu-13-992232-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5469/9637940/88a15021e21a/fimmu-13-992232-g001.jpg

相似文献

[1]
Preclinical and clinical studies of CAR-NK-cell therapies for malignancies.

Front Immunol. 2022

[2]
Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity.

Br J Haematol. 2021-4

[3]
CAR-NK for tumor immunotherapy: Clinical transformation and future prospects.

Cancer Lett. 2019-11-29

[4]
CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies.

Stem Cell Res Ther. 2021-7-2

[5]
Advances in CAR-NK cell therapy for hematological malignancies.

Front Immunol. 2024

[6]
IPSC-derived CAR-NK cells for cancer immunotherapy.

Biomed Pharmacother. 2023-9

[7]
Novel insights in CAR-NK cells beyond CAR-T cell technology; promising advantages.

Int Immunopharmacol. 2022-5

[8]
Engineering Natural Killer Cells for Cancer Immunotherapy.

Mol Ther. 2017-8-2

[9]
Current progress of chimeric antigen receptor (CAR) T versus CAR NK cell for immunotherapy of solid tumors.

Life Sci. 2024-1-15

[10]
Challenges of chimeric antigen receptor-T/natural killer cell therapy in the treatment of solid tumors: focus on colorectal cancer and evaluation of combination therapies.

Mol Cell Biochem. 2023-5

引用本文的文献

[1]
Engineered iPSC-derived natural killer cells: recent innovations in translational innate anti-cancer immunotherapy.

Clin Transl Immunology. 2025-7-10

[2]
CAR-NK cells: harnessing the power of natural killers for advanced cancer therapy.

Front Immunol. 2025-5-30

[3]
The Role of NK Cells in Cancer Immunotherapy: Mechanisms, Evasion Strategies, and Therapeutic Advances.

Biomedicines. 2025-4-2

[4]
CD147-CAR-NK cell therapy shows minimal toxicities in human CD147 transgenic mouse model with solid tumors.

Mol Ther Oncol. 2025-2-26

[5]
Agent-based modeling of cellular dynamics in adoptive cell therapy.

bioRxiv. 2025-2-21

[6]
Novel gene manipulation approaches to unlock the existing bottlenecks of CAR-NK cell therapy.

Front Cell Dev Biol. 2025-2-11

[7]
The evolution of cancer immunotherapy: a comprehensive review of its history and current perspectives.

Korean J Clin Oncol. 2024-12

[8]
Soluble factors released by peripheral blood-derived CAR-NK cells cause bystander myeloid cell activation.

Front Immunol. 2024-12-24

[9]
Targeting Cancer: Microenvironment and Immunotherapy Innovations.

Int J Mol Sci. 2024-12-18

[10]
c-MET and the immunological landscape of cancer: novel therapeutic strategies for enhanced anti-tumor immunity.

Front Immunol. 2024-11-27

本文引用的文献

[1]
Carrier-free multifunctional nanomedicine for intraperitoneal disseminated ovarian cancer therapy.

J Nanobiotechnology. 2022-2-22

[2]
IL-13Rα2 humanized scFv-based CAR-T cells exhibit therapeutic activity against glioblastoma.

Mol Ther Oncolytics. 2022-1-10

[3]
piggyBac system to co-express NKG2D CAR and IL-15 to augment the persistence and anti-AML activity of human peripheral blood NK cells.

Mol Ther Methods Clin Dev. 2021-11-4

[4]
NK Cell-Mediated Eradication of Ovarian Cancer Cells with a Novel Chimeric Antigen Receptor Directed against CD44.

Biomedicines. 2021-9-28

[5]
Targeting human leukocyte antigen G with chimeric antigen receptors of natural killer cells convert immunosuppression to ablate solid tumors.

J Immunother Cancer. 2021-10

[6]
Suppression of breast cancer cells resistant to a pure anti-estrogen with CAR-transduced natural killer cells.

Am J Cancer Res. 2021-9-15

[7]
High-Affinity Chimeric Antigen Receptor With Cross-Reactive scFv to Clinically Relevant EGFR Oncogenic Isoforms.

Front Oncol. 2021-9-10

[8]
CXCR4 and anti-BCMA CAR co-modified natural killer cells suppress multiple myeloma progression in a xenograft mouse model.

Cancer Gene Ther. 2022-5

[9]
Novel BCMA-OR-CD38 tandem-dual chimeric antigen receptor T cells robustly control multiple myeloma.

Oncoimmunology. 2021

[10]
NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma.

Blood Cancer J. 2021-8-14

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索